Drugs Made in America Acquisition CORP 8-K filings

Drugs Made In America Acquisition Corp. (DMAA) has amended its merger agreement with Power Analytics Global Corp (PAGC), introducing changes to sponsor shares, rights treatment, and financing, while also outlining a contingent amendment for a potential three-party combination.

Drugs Made In America Acquisition Corp. (DMAA) has entered into a definitive merger agreement to acquire Power Analytics Global Corp (PAGC) at a $1 billion target enterprise valuation.

Shareholders approved a 12-month extension to complete a business combination, with 9.44 million shares redeemed.

Drugs Made In America Acquisition Corp. has formalized compensation agreements for its CFO and CEO, including monthly fees and share grants tied to a future business combination.

Drugs Made In America Acquisition Corp. has entered into a non-binding letter of intent to combine with Power Analytics Global Corp., valuing the target at approximately $1 billion.

Drugs Made In America Acquisition Corp. secured an initial $100,000 interim convertible note from BV Advisory Partners, LLC, as part of a larger $500,000 financing commitment to pursue a new business combination in enterprise technology.

Drugs Made In America Acquisition Corp. confirmed its trust account holds $241.3 million, unaffected by improper withdrawals from an affiliate's working capital.

Drugs Made In America Acquisition Corp.'s CEO Lynn Stockwell resigned following discovery of significant fund withdrawals by the company's sponsor.

Drugs Made In America Acquisition Corp. announced the resignation of its CFO, Glenn Worman, and the appointment of Saleem Elmasri, a seasoned financial professional, effective November 17, 2025.

Drugs Made In America Acquisition Corp. finalized its over-allotment option and private placement, increasing the funds held in its trust account to $231.15 million.

Drugs Made In America Acquisition Corp. will allow separate trading of its ordinary shares and rights starting February 25, 2025.

Drugs Made In America Acquisition Corp. successfully completed its initial public offering (IPO) of 20,000,000 units at $10.00 per unit, generating gross proceeds of $200 million, and a simultaneous private placement of 400,000 units to its sponsor for $4 million.

Drugs Made In America Acquisition Corp. successfully closed its initial public offering, raising $200 million to pursue a business combination in the pharmaceutical industry.